You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMefenamic acid
Accession NumberDB00784  (APRD00730)
TypeSmall Molecule
GroupsApproved
DescriptionA non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]
Structure
Thumb
Synonyms
Acide méfénamique
Acido mefenamico
Acidum mefenamicum
CI-473
CN 35355
CN-35355
INF 3355
INF-3355
Mefenaminsaeure
Mefenaminsäure
N-(2,3-Xylyl)-2-aminobenzoic acid
N-2,3-Xylylanthranilic acid
Ponstel
External Identifiers
  • CI 473
  • CN 35355
  • INF 3355
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-mefenamic AcidCapsule250 mgOralDominion Pharmacal1998-09-17Not applicableCanada
MefenamicCapsule250 mgOralAa Pharma Inc1996-11-06Not applicableCanada
Mefenamic AcidCapsule250 mg/1OralPrasco Laboratories1967-03-28Not applicableUs
Mefenamic-250Capsule250 mgOralPro Doc Limitee1997-08-062009-07-23Canada
Novo-mefenamic Capsules 250mgCapsule250 mgOralNovopharm LimitedNot applicableNot applicableCanada
Nu-mefenamic 250 mgCapsule250 mgOralNu Pharm Inc1996-10-162012-09-04Canada
PMS-mefenamic AcidCapsule250 mgOralPharmascience Inc1998-04-16Not applicableCanada
PonstanCapsule250 mgOralAspri Pharma Canada Inc1966-12-31Not applicableCanada
PonstelCapsule250 mg/1OralShionogi Inc.1967-03-28Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mefenamic AcidCapsule250 mg/1OralPaddock Laboratories, LLC2010-11-192016-03-01Us
Mefenamic AcidCapsule250 mg/1OralQualitest Pharmaceuticals2014-06-02Not applicableUs
Mefenamic AcidCapsule250 mg/1OralBelcher Pharmaceuticals,LLC2015-06-25Not applicableUs
Mefenamic AcidCapsule250 mg/1OralLupin Pharmaceuticals, Inc.2011-07-22Not applicableUs
Mefenamic AcidCapsule250 mg/1OralSolubiomix2016-03-232016-10-13Us
Mefenamic AcidCapsule250 mg/1OralBreckenridge Pharmaceutical, Inc.2014-10-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CoslanParke Davis
LysalgoSIT
MefacitSecFarm
ParkemedPfizer
PonalarCoronet Crown
Ponstan FortePfizer
PonstylPfizer
Ponstyl FortPfizer
PontalDaiichi Sankyo
TanstonPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII367589PJ2C
CAS number61-68-7
WeightAverage: 241.2851
Monoisotopic: 241.110278729
Chemical FormulaC15H15NO2
InChI KeyHYYBABOKPJLUIN-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
IUPAC Name
2-[(2,3-dimethylphenyl)amino]benzoic acid
SMILES
CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
Structured Indications
PharmacodynamicsMefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.
Mechanism of actionMefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionMefenamic acid is rapidly absorbed after oral administration.
Volume of distribution
  • 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
Protein binding90%
Metabolism

Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.

Route of eliminationThe fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.
Half life2 hours
Clearance
  • Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
ToxicityOral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mefenamic Acid Action PathwayDrug actionSMP00109
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabMefenamic acid may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Mefenamic acid can be increased when it is combined with Abiraterone.Approved
AcebutololMefenamic acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Aceclofenac.Approved
AcenocoumarolMefenamic acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMefenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mefenamic acid.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.Approved
AliskirenMefenamic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMefenamic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mefenamic acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Amcinonide.Approved
AmikacinMefenamic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMefenamic acid may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Mefenamic acid can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Mefenamic acid.Approved
AmrubicinMefenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMefenamic acid may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Anisodamine.Investigational
annamycinMefenamic acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Antipyrine.Approved
Antithrombin III humanMefenamic acid may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Mefenamic acid may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanMefenamic acid may increase the anticoagulant activities of Apixaban.Approved
ApramycinMefenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Mefenamic acid can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinMefenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMefenamic acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMefenamic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMefenamic acid may decrease the antihypertensive activities of Arotinolol.Approved
AtenololMefenamic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mefenamic acid.Approved
BalsalazideMefenamic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminMefenamic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMefenamic acid may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mefenamic acid.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mefenamic acid.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mefenamic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololMefenamic acid may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Betulinic Acid.Investigational
BevantololMefenamic acid may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mefenamic acid.Approved, Investigational
BisoprololMefenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMefenamic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMefenamic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bucillamine.Investigational
BucindololMefenamic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Budesonide.Approved
BufuralolMefenamic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMefenamic acid may decrease the diuretic activities of Bumetanide.Approved
BupranololMefenamic acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mefenamic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mefenamic acid.Experimental
CapecitabineThe metabolism of Mefenamic acid can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mefenamic acid.Approved
CarbamazepineThe metabolism of Mefenamic acid can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mefenamic acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMefenamic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMefenamic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Celecoxib.Approved, Investigational
CeliprololMefenamic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Mefenamic acid can be increased when it is combined with Ceritinib.Approved
CertoparinMefenamic acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefenamic acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mefenamic acid.Approved
CholecalciferolThe metabolism of Mefenamic acid can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mefenamic acid.Approved
CinoxacinMefenamic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMefenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidMefenamic acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clonixin.Approved
ClopidogrelThe metabolism of Mefenamic acid can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mefenamic acid.Vet Approved
ClotrimazoleThe metabolism of Mefenamic acid can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Curcumin.Investigational
CyclosporineMefenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Mefenamic acid can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with D-Limonene.Investigational
Dabigatran etexilateMefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib.Approved
DalteparinMefenamic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMefenamic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinMefenamic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Mefenamic acid can be increased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Mefenamic acid can be decreased when combined with Delavirdine.Approved
DesirudinMefenamic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mefenamic acid.Approved
DextranMefenamic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mefenamic acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Mefenamic acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Mefenamic acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mefenamic acid.Approved, Vet Approved
DicoumarolMefenamic acid may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mefenamic acid.Approved
DihydrostreptomycinMefenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mefenamic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mefenamic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mefenamic acid.Approved
DoxorubicinMefenamic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMefenamic acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Mefenamic acid is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ebselen.Investigational
Edetic AcidMefenamic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMefenamic acid may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Mefenamic acid can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mefenamic acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mefenamic acid.Approved
EnoxacinMefenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinMefenamic acid may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Epirizole.Approved
EpirubicinMefenamic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMefenamic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mefenamic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mefenamic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Equilin.Approved
EsmololMefenamic acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Estrone sulfate.Approved
Etacrynic acidMefenamic acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mefenamic acid.Approved, Investigational
Ethyl biscoumacetateMefenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Mefenamic acid can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with exisulind.Investigational
FelodipineThe metabolism of Mefenamic acid can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mefenamic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mefenamic acid.Vet Approved
FleroxacinMefenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mefenamic acid.Approved, Withdrawn
FloxuridineThe metabolism of Mefenamic acid can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with fluasterone.Investigational
FluconazoleThe metabolism of Mefenamic acid can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fludrocortisone.Approved
FluindioneMefenamic acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMefenamic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Mefenamic acid can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mefenamic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mefenamic acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Mefenamic acid can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Mefenamic acid can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mefenamic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxMefenamic acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMefenamic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mefenamic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mefenamic acid.Approved
FosphenytoinThe metabolism of Mefenamic acid can be increased when combined with Fosphenytoin.Approved
FramycetinMefenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMefenamic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateMefenamic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMefenamic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMefenamic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mefenamic acid.Approved, Withdrawn
GemfibrozilThe metabolism of Mefenamic acid can be decreased when combined with Gemfibrozil.Approved
GemifloxacinMefenamic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMefenamic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMefenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMefenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinMefenamic acid may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mefenamic acid is combined with HE3286.Investigational
HeparinMefenamic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Higenamine.Investigational
HirulogMefenamic acid may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Mefenamic acid is combined with HMPL-004.Investigational
HydralazineMefenamic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mefenamic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mefenamic acid.Approved
Hygromycin BMefenamic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icatibant.Approved
IdarubicinMefenamic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxMefenamic acid may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mefenamic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mefenamic acid.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mefenamic acid.Approved
IndenololMefenamic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Mefenamic acid can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Indoprofen.Withdrawn
INNO-206Mefenamic acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Mefenamic acid can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Istaroxime.Investigational
KanamycinMefenamic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Mefenamic acid can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mefenamic acid.Approved
LabetalolMefenamic acid may decrease the antihypertensive activities of Labetalol.Approved
LapatinibThe metabolism of Mefenamic acid can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mefenamic acid.Approved, Investigational
LeflunomideThe metabolism of Mefenamic acid can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinMefenamic acid may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMefenamic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMefenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mefenamic acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mefenamic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mefenamic acid.Approved
LomefloxacinMefenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Mefenamic acid can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lornoxicam.Approved
LosartanThe metabolism of Mefenamic acid can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Mefenamic acid can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mefenamic acid.Approved, Investigational
LumacaftorThe serum concentration of Mefenamic acid can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mefenamic acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mefenamic acid.Approved
ME-609The risk or severity of adverse effects can be increased when Mefenamic acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Medrysone.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meloxicam.Approved, Vet Approved
MesalazineMefenamic acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mefenamic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMefenamic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid.Approved
MetoprololMefenamic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMefenamic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Mefenamic acid can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mefenamic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mefenamic acid.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mefenamic acid.Approved
MoxifloxacinMefenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mefenamic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nabumetone.Approved
NadololMefenamic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMefenamic acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMefenamic acid may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mefenamic acid.Approved
Nalidixic AcidMefenamic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Mefenamic acid is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Mefenamic acid is combined with NCX 4016.Investigational
NeamineMefenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMefenamic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMefenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nepafenac.Approved
NetilmicinMefenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Mefenamic acid can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Mefenamic acid can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nitroaspirin.Investigational
NorfloxacinMefenamic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMefenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mefenamic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mefenamic acid.Approved
OlsalazineMefenamic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mefenamic acid.Investigational
OmeprazoleThe metabolism of Mefenamic acid can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Orgotein.Vet Approved
OtamixabanMefenamic acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxaprozin.Approved
OxprenololMefenamic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Parecoxib.Approved
ParomomycinMefenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinMefenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMefenamic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMefenamic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMefenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mefenamic acid.Approved
PhenindioneMefenamic acid may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Mefenamic acid can be increased when combined with Phenobarbital.Approved
PhenprocoumonMefenamic acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Mefenamic acid can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mefenamic acid.Approved, Investigational
PindololMefenamic acid may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Mefenamic acid can be decreased when combined with Pioglitazone.Approved, Investigational
PirarubicinMefenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMefenamic acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mefenamic acid.Approved, Investigational
PlicamycinMefenamic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mefenamic acid.Approved
PractololMefenamic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mefenamic acid.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Mefenamic acid can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Mefenamic acid can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Propacetamol.Approved
PropranololMefenamic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mefenamic acid.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mefenamic acid.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mefenamic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mefenamic acid.Vet Approved
Protein CMefenamic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanMefenamic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMefenamic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMefenamic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Mefenamic acid is combined with PTC299.Investigational
PuromycinMefenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Mefenamic acid can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mefenamic acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mefenamic acid.Approved
QuinineThe metabolism of Mefenamic acid can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Mefenamic acid can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mefenamic acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mefenamic acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.Experimental, Investigational
ReviparinMefenamic acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMefenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Mefenamic acid can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Mefenamic acid can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Mefenamic acid can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanMefenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe metabolism of Mefenamic acid can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinMefenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mefenamic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mefenamic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mefenamic acid.Investigational
SecobarbitalThe metabolism of Mefenamic acid can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Mefenamic acid can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinMefenamic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Mefenamic acid can be decreased when combined with Sorafenib.Approved, Investigational
SotalolMefenamic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMefenamic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMefenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMefenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mefenamic acid.Approved
SpironolactoneMefenamic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Mefenamic acid is combined with SRT501.Investigational
StiripentolThe metabolism of Mefenamic acid can be decreased when combined with Stiripentol.Approved
StreptomycinMefenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMefenamic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Mefenamic acid can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Mefenamic acid can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineMefenamic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Mefenamic acid can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mefenamic acid.Approved
SulodexideMefenamic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mefenamic acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Suprofen.Approved, Withdrawn
TacrolimusMefenamic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mefenamic acid.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mefenamic acid.Approved
TamoxifenThe metabolism of Mefenamic acid can be decreased when combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mefenamic acid.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mefenamic acid.Approved, Investigational
TemafloxacinMefenamic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mefenamic acid.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mefenamic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Mefenamic acid can be decreased when combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Mefenamic acid can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Mefenamic acid can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiludronate.Approved, Vet Approved
TimololMefenamic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tixocortol.Approved
TobramycinMefenamic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Mefenamic acid can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mefenamic acid.Approved
TorasemideMefenamic acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mefenamic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mefenamic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mefenamic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMefenamic acid may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mefenamic acid.Approved, Vet Approved
TrimethoprimThe metabolism of Mefenamic acid can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Trisalicylate-choline.Approved
TrovafloxacinMefenamic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mefenamic acid.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Mefenamic acid can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinMefenamic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Mefenamic acid can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mefenamic acid.Approved
VoriconazoleThe metabolism of Mefenamic acid can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinMefenamic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMefenamic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Mefenamic acid may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Mefenamic acid can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mefenamic acid.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zomepirac.Withdrawn
ZorubicinMefenamic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Take with food.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AG01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (135 KB)
MSDSDownload (59.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.762
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7948
P-glycoprotein inhibitor INon-inhibitor0.8632
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.9191
CYP450 2C9 substrateNon-substrate0.6814
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7019
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9483
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9175
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6613
Ames testNon AMES toxic0.812
CarcinogenicityNon-carcinogens0.5833
BiodegradationNot ready biodegradable0.822
Rat acute toxicity2.5445 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9727
hERG inhibition (predictor II)Non-inhibitor0.8706
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg
CapsuleOral250 mg/1
Prices
Unit descriptionCostUnit
Ponstel 250 mg capsule11.85USD capsule
Mefenamic acid powder2.85USD g
Ponstel 250 mg kapseals1.59USD each
Apo-Mefenamic 250 mg Capsule0.52USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231 °CPhysProp
water solubility20 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.12HANSCH,C ET AL. (1995)
logS-3.78ADME Research, USCD
pKa4.2SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP4.58ALOGPS
logP5.4ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.89ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.88 m3·mol-1ChemAxon
Polarizability26.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Aminobenzoic acid
  • Benzoic acid
  • Substituted aniline
  • Benzoyl
  • Aniline
  • Vinylogous amide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84. [PubMed:7832763 ]
  2. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study. Eur J Pharmacol. 2007 Feb 5;556(1-3):190-9. Epub 2006 Oct 27. [PubMed:17150210 ]
  3. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. Eur J Pharmacol. 2005 Mar 28;511(2-3):137-42. [PubMed:15792781 ]
  4. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21. [PubMed:9626023 ]
  5. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW, Powell JT: Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999 Jul 6;100(1):48-54. [PubMed:10393680 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Sinniah R, Lye WC: Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid. Clin Nephrol. 2001 Mar;55(3):254-8. [PubMed:11316248 ]
  2. Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, Chang KA, Kim S, Suh YH: Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol Pharmacol. 2006 Jan;69(1):76-84. Epub 2005 Oct 13. [PubMed:16223958 ]
  3. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21. [PubMed:9626023 ]
  4. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84. [PubMed:7832763 ]
  5. Laudanno OM, Cesolari JA, Esnarriaga J, Flaherty P, Vada J, Guastalli G, San Miguel P, Bedini OA: [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats]. Acta Gastroenterol Latinoam. 1998;28(3):249-55. [PubMed:9773153 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23